Search results for " atherosclerosis"

showing 10 items of 159 documents

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

2017

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

0301 basic medicine030204 cardiovascular system & hematologylaw.invention0302 clinical medicinec-reactive proteinRandomized controlled triallawCardiovascular Diseasemiddle ageddouble-blind methodantibodiesMyocardial infarctionhumansStrokeinterleukin-1betabiologyAntibodies MonoclonaldrugGeneral MedicineLipidAged; anti-inflammatory agents; antibodies; monoclonal; antibodies; monoclonal; humanized; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship; drug; double-blind method; female; humans; incidence; infections; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; strokestrokeAnti-Inflammatory AgentagedEditorialfemalemyocardial infarctionAtherosclerosiMonoclonalsecondary preventionHumanmedicine.drugmedicine.medical_specialtymonoclonalNeutropeniaAntibodies Monoclonal HumanizedInfectionsPlaceboaged; anti-inflammatory agents; antibodies monoclonal; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship drug; double-blind method; female; humans; incidence; infection; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; stroke; medicine (all)anti-inflammatory agentsdose-response relationshiplipids03 medical and health sciencesmaleInternal medicinemedicineneutropeniamedicine (all)Dose-Response Relationship Drugbusiness.industryAntiinflammatory Therapy Canakinumab for Atherosclerotic DiseaseC-reactive proteinmedicine.diseaseinfectioncardiovascular diseasesSurgeryCanakinumab030104 developmental biologyincidencebiology.proteinatherosclerosisbusinessNew England journal of medicine
researchProduct

The function of matrix metalloproteinase-9 (MMP-9) and its tissue inhibitor (TIMP-1) in several clinical conditions: Results and analysis of our surv…

2021

The goal of this research was to evaluate the plasma concentration of MMP-9 and its tissue inhibitor (TIMP-1) in different clinical conditions. It included several groups of subjects: 31 overweight subjects; 91 obese adults divided into two subgroups according to the BMI value (BMI 30–35 Kg/m2 and BMI > 35 Kg/m2); 90 subjects with metabolic syndrome (MS) divided into two subgroups (with and without diabetes mellitus); 100 subjects with preclinical carotid atherosclerosis (PCA) divided according to the number of cardiovascular risk factors and to the insulin resistance degree; 48 subjects with obstructive sleep apnoea syndrome (OSAS) divided according to the apnoea/hypopnea index (AHI); 2…

0301 basic medicineAdultmedicine.medical_specialtyPhysiologymedicine.medical_treatment030204 cardiovascular system & hematologyOverweightAdult CKD Humans metabolic syndrome Matrix Metalloproteinase 9 Metabolic Syndrome MMP-9 Obesity OSAS preclinical carotid atherosclerosis Sleep Apnea Obstructive TIMP-1 Tissue Inhibitor of Metalloproteinase-103 medical and health sciences0302 clinical medicineInsulin resistancePhysiology (medical)Diabetes mellitusInternal medicinemedicineHumansObesityDialysisMetabolic SyndromeSleep Apnea ObstructiveTissue Inhibitor of Metalloproteinase-1business.industryHematologymedicine.diseaseObesity030104 developmental biologyMatrix Metalloproteinase 9medicine.symptomMetabolic syndromeCardiology and Cardiovascular MedicinebusinessHypopneaKidney diseaseClinical hemorheology and microcirculation
researchProduct

Cellular and molecular basis of the imbalance between vascular damage and repair in ageing and age-related diseases: As biomarkers and targets for ne…

2016

Preclinical and clinical studies suggest that specific subsets of cells isolated from the peripheral blood, play an essential role in the imbalance of damage and repair during age-associated diseases, such as metabolic syndrome, diabetes, atherosclerosis, neurodegenerative diseases, osteoporosis and cancer. Endogenous regeneration of the vessel wall involves cells of the vascular wall, inflammatory cells, circulating precursors, and mature endothelial cells, which are capable to restore the endothelium in a concerted interaction. Early detection of such imbalances with specific biomarkers may reduce age-associated diseases and subsequent cardiovascular events. Likewise, new strategies have …

0301 basic medicineAgingEndotheliumCellStimulationBiologyVascular disease03 medical and health sciencesDiabetes mellitusStem and progenitor cellsNeoplasmsmedicineBiomarkers TumorDiabetes MellitusStem and progenitor cells Biomarkers Ageing Vascular diseaseAnimalsHumansMetabolic SyndromeTumorVascular diseaseEndogenous regenerationCancerNeurodegenerative Diseasesmedicine.diseaseAtherosclerosisAgeing; Biomarkers; Stem and progenitor cells; Vascular disease; Animals; Biomarkers Tumor; Humans; Aging; Atherosclerosis; Diabetes Mellitus; Metabolic Syndrome; Neoplasms; Neurodegenerative Diseases; OsteoporosisAgeing030104 developmental biologymedicine.anatomical_structureAgeingImmunologyCancer researchOsteoporosisBiomarkersDevelopmental Biology
researchProduct

Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study

2017

Abstract Background Familial hypercholesterolemia (FH) is an autosomal dominant disease characterized by elevated plasma levels of LDL-cholesterol that confers an increased risk of premature atherosclerotic cardiovascular disease. Early identification and treatment of FH patients can improve prognosis and reduce the burden of cardiovascular mortality. Aim of this study was to perform the mutational analysis of FH patients identified through a collaboration of 20 Lipid Clinics in Italy (LIPIGEN Study). Methods We recruited 1592 individuals with a clinical diagnosis of definite or probable FH according to the Dutch Lipid Clinic Network criteria. We performed a parallel sequencing of the major…

0301 basic medicineApolipoprotein ECandidate geneSettore MED/09 - Medicina InternaDatabases FactualApolipoprotein BDNA Mutational AnalysisFamilial hypercholesterolemia030204 cardiovascular system & hematologyCompound heterozygosityPCSK90302 clinical medicineRisk FactorsReceptorsGeneticsHomozygoteAutosomal dominant traitPathogenic variantsGeneral MedicinePrognosisAPOB; Familial hypercholesterolemia; LDLR; PCSK9; Pathogenic variantsCholesterolPhenotypeItalyAutosomal Recessive HypercholesterolemiaApolipoprotein B-100lipids (amino acids peptides and proteins)Proprotein Convertase 9APOBCardiology and Cardiovascular MedicinePreliminary DataGenetic MarkersFamilial hypercholesterolemiaLDLRPCSK9APOBPathogenic variantsHeterozygoteFamilial hypercholesterolemiaBiologyPathogenic variantLDLHyperlipoproteinemia Type II03 medical and health sciencesDatabasesmedicineInternal MedicineHumansAPOB; Familial hypercholesterolemia; LDLR; Pathogenic variants; PCSK9; Internal Medicine; Cardiology and Cardiovascular MedicineGenetic Predisposition to DiseaseFactualPCSK9Settore MED/13 - ENDOCRINOLOGIAAPOB; Familial hypercholesterolemia; LDLR; Pathogenic variants; PCSK9; Cardiology and Cardiovascular Medicine; Internal Medicinemedicine.diseaseAtherosclerosis030104 developmental biologyLDLRReceptors LDLMutationbiology.proteinAPOB; Familial hypercholesterolemia; LDLR; Pathogenic variants; PCSK9; Apolipoprotein B-100; Atherosclerosis; Cholesterol; DNA Mutational Analysis; Databases Factual; Genetic Markers; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; Italy; Phenotype; Preliminary Data; Prognosis; Proprotein Convertase 9; Receptors LDL; Risk Factors; Mutation; Internal Medicine; Cardiology and Cardiovascular Medicine
researchProduct

Low level activity thresholds for changes in NMR biomarkers and genes in high risk subjects for type 2 diabetes

2017

AbstractOur objectives were to determine if there are quantitative associations between amounts and intensities of physical activities (PA) on NMR biomarkers and changes in skeletal muscle gene expressions in subjects with high risk for type 2 diabetes (T2D) performing a 3-month PA intervention. We found that PA was associated with beneficial biomarker changes in a factor containing several VLDL and HDL subclasses and lipids in principal component analysis (P = <0.01). Division of PA into quartiles demonstrated significant changes in NMR biomarkers in the 2nd - 4th quartiles compared to the 1st quartile representing PA of less than 2850 daily steps (P = 0.0036). Mediation analysis of PA-…

0301 basic medicineBlood GlucoseMaleVery low-density lipoprotein[SDV]Life Sciences [q-bio]prévention des maladieslcsh:MedicineAdipose tissueMuscle ProteinsType 2 diabetes030204 cardiovascular system & hematologyOverweight0302 clinical medicinemaladie cardiovasculairelcsh:ScienceComputingMilieux_MISCELLANEOUSBODY-WEIGHT CHANGEMultidisciplinaryMiddle AgedMagnetic Resonance Imaging[SDV] Life Sciences [q-bio]ADIPOSE-TISSUEBiomarker (medicine)SKELETAL-MUSCLEFemalemedicine.symptombiomarqueurINSULIN-RESISTANCE ATHEROSCLEROSISAutre (Sciences du Vivant)Adultmedicine.medical_specialtydiabète de type 2expression géniqueCarbohydrate metabolismALL-CAUSEArticle03 medical and health sciencesMedical researchLIPID-METABOLISMInternal medicineDiabetes mellitusmedicineAPOLIPOPROTEIN-D POLYMORPHISMHumansObesityNUCLEAR-MAGNETIC-RESONANCEMuscle SkeletalExercisebusiness.industryMORTALITYlcsh:RLipid metabolismsurpoidsLIPOPROTEIN PARTICLE-SIZEmedicine.disease030104 developmental biologyEndocrinologyPHYSICAL-ACTIVITYDiabetes Mellitus Type 2Gene Expression Regulationlcsh:QbusinessBiomarkers
researchProduct

Renal haemodynamics and coronary atherosclerotic burden are associated in patients with hypertension and mild coronary artery disease

2019

Intrarenal hemodynamic alterations are independent predictors of cardiovascular events in different populations. It has been hypothesized that there is an association between renal hemodynamics and coronary atherosclerotic burden in patients with hypertension. Therefore, the present study examined the associations between renal hemodynamics, coronary atherosclerotic burden and carotid atherosclerotic disease. A total of 130 patients with hypertension aged between 30-80 years who had been referred for an elective coronary angiography were enrolled in the present study. A duplex ultrasound of the intrarenal vasculature was performed to evaluate the resistive index (RI), pulsatility index (PI)…

0301 basic medicineCancer Researchmedicine.medical_specialtyEjection fractionbusiness.industrySignificant differenceCancerHemodynamicsRenal haemodynamicsGeneral MedicineArticlesmedicine.diseaseCoronary artery disease03 medical and health sciences030104 developmental biology0302 clinical medicineImmunology and Microbiology (miscellaneous)030220 oncology & carcinogenesisInternal medicineCardiologymedicineArterial stiffnessIn patientIntrarenal resistive index (RI) - coronary disease - coronary atherosclerosisbusiness
researchProduct

Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN)

2017

Background and aims: Primary dyslipidemias are a heterogeneous group of disorders characterized by abnormal levels of circulating lipoproteins. Among them, familial hypercholesterolemia is the most common lipid disorder that predisposes for premature cardiovascular disease. We set up an Italian nationwide network aimed at facilitating the clinical and genetic diagnosis of genetic dyslipidemias named LIPIGEN (LIpid TransPort Disorders Italian GEnetic Network). Methods: Observational, multicenter, retrospective and prospective study involving about 40 Italian clinical centers. Genetic testing of the appropriate candidate genes at one of six molecular diagnostic laboratories serving as nationw…

0301 basic medicineCandidate geneGenetic testingSettore MED/09 - Medicina InternaDatabases FactualDNA Mutational AnalysisDiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematology0302 clinical medicineDyslipidemias; Genetic testing; National network; Internal Medicine; Cardiology and Cardiovascular MedicineRisk FactorsProspective StudiesProgram DevelopmentProspective cohort studymedicine.diagnostic_testGeneral MedicinePrognosisCholesterolPhenotypeItalyCardiology and Cardiovascular MedicineGenetic Markersmedicine.medical_specialtyNational networkDyslipidemias; Genetic testing; National networkMEDLINEHyperlipoproteinemia Type II03 medical and health sciencesDatabasesInternal medicinemedicineInternal MedicineHumansGenetic Predisposition to DiseaseFactualGenetic testingRetrospective StudiesDyslipidemiasbusiness.industrySettore MED/13 - ENDOCRINOLOGIARetrospective cohort studymedicine.diseaseAtherosclerosisDyslipidemias; Genetic testing; National network; Atherosclerosis; Cholesterol; DNA Mutational Analysis; Databases Factual; Genetic Markers; Genetic Predisposition to Disease; Humans; Hyperlipoproteinemia Type II; Italy; Phenotype; Prognosis; Program Development; Prospective Studies; Retrospective Studies; Risk Factors; Mutation; Internal Medicine; Cardiology and Cardiovascular Medicine030104 developmental biologyEndocrinologyDyslipidemiaGenetic markerMutationbusiness
researchProduct

Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis.

2018

Abstract BACKGROUND AND AIM: Recent studies suggest an association between HCV infection and cardiovascular damage, including carotid atherosclerosis, with a possible effect of HCV clearance on cardiovascular outcomes. We aimed to examine whether HCV eradication by direct antiviral agents (DAA) improves carotid atherosclerosis in HCV-infected patients with advanced fibrosis/compensated cirrhosis. MATERIALS AND METHODS: One hundred eighty-two consecutive HCV patients with advanced fibrosis or compensated cirrhosis were evaluated by virological, anthropometric and metabolic measurements. All patients underwent DAA-based antiviral therapy according to AISF/EASL guidelines. Intima-media thickne…

0301 basic medicineCarotid atherosclerosisCarotid Artery DiseasesMalemedicine.medical_specialtyCirrhosisSVRSustained Virologic ResponseHepatitis C virusHepacivirusmedicine.disease_causeGastroenterologyAntiviral AgentsCarotid Intima-Media Thickness03 medical and health sciencesLiver disease0302 clinical medicineRisk FactorsInternal medicineDiabetes mellitusmedicineGlucose homeostasisHumansIn patientProspective StudiesDAAHepatologybusiness.industryHepatitis C ChronicMiddle Agedmedicine.disease030104 developmental biologyTreatment OutcomeATHEROSCLEROSISHCVcardiovascular system030211 gastroenterology & hepatologyFemalebusinessDirect actingFollow-Up Studies
researchProduct

Diabetic macroangiopathy: Pathogenetic insights and novel therapeutic approaches with focus on high glucose-mediated vascular damage

2018

Diabetic macroangiopathy - a specific form of accelerated atherosclerosis - is characterized by intra-plaque new vessel formation due to excessive/abnormal neovasculogenesis and angiogenesis, increased vascular permeability of the capillary vessels, and tissue edema, resulting in frequent atherosclerotic plaque hemorrhage and plaque rupture. Mechanisms that may explain the premature and rapidly progressive nature of atherosclerosis in diabetes are multiple, and to a large extent still unclear. However, mechanisms related to hyperglycemia certainly play an important role. These include a dysregulated vascular regeneration. In addition, oxidative and hyperosmolar stresses, as well as the acti…

0301 basic medicineProteomicsPhysiologyAngiogenesisAquaporinMetabolomicVascular permeability030204 cardiovascular system & hematologyDiabeteBioinformaticsAquaporins03 medical and health sciences0302 clinical medicineDiabetes mellitusMedicineMetabolomicsMacrovascular diseasePharmacologybusiness.industryAquaporinRegeneration (biology)DiabetesPlaque rupturemedicine.diseaseAtherosclerosisAquaporins; Atherosclerosis; Diabetes; Hyperglycemia; Metabolomics; Proteomics030104 developmental biologyAtherosclerosiHyperglycemiaHigh glucoseMolecular Medicinebusiness
researchProduct

Galectin-3 in acute coronary syndrome

2017

Acute coronary syndrome (ACS) is a very common cause of hospitalizations worldwide each year. In the past decades biomarkers have become an indispensable tool for diagnosis, risk stratification and prognosis of cardiovascular disease, including ACS. Despite Troponin is considered the gold standard in diagnosis of ACS, several molecules have been investigated to identify predictive biomarkers of prognosis. Among these, Gal-3 has emerged as a promising prognostic marker. It has a pivotal role in inflammation and fibrosis. Both experimental and clinical studies have shown Gal-3 is an independent predictor of all-cause mortality, cardiovascular death and occurrence of HF following ACS. This art…

0301 basic medicinemedicine.medical_specialtyAcute coronary syndromeAcute coronary syndrome; AMI; Galectin-3; Heart failure; Myocardial infarction; Prognosis; Acute Coronary Syndrome; Atherosclerosis; Biomarkers; Galectin 3; Heart Failure; Humans; Myocardial Infarction; Prognosis; Evidence-Based Medicine; Clinical BiochemistryPrognosiGalectinsGalectin 3Clinical BiochemistryMyocardial InfarctionDisease030204 cardiovascular system & hematologyAMI03 medical and health sciences0302 clinical medicineFibrosismedicineHumansGalectin-3Myocardial infarctionIntensive care medicineHeart FailureEvidence-Based Medicinebiologybusiness.industryGold standardGeneral MedicineBlood ProteinsBiomarkermedicine.diseaseAtherosclerosisPrognosisTroponin030104 developmental biologyGalectin-3Heart failureAtherosclerosibiology.proteinAcute coronary syndromebusinessBiomarkersHuman
researchProduct